Free Trial
NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

Candel Therapeutics logo
$5.44 +0.12 (+2.35%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Candel Therapeutics Stock (NASDAQ:CADL)

Advanced

Key Stats

Today's Range
$5.33
$5.51
50-Day Range
$4.79
$6.55
52-Week Range
$3.79
$14.60
Volume
447,018 shs
Average Volume
989,726 shs
Market Capitalization
$298.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.20
Consensus Rating
Moderate Buy

Company Overview

Candel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

CADL MarketRank™: 

Candel Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 408th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Candel Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Candel Therapeutics has a consensus price target of $19.20, representing about 255.2% upside from its current price of $5.41.

  • Amount of Analyst Coverage

    Candel Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Candel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Candel Therapeutics is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Candel Therapeutics is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Candel Therapeutics has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Candel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.11% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently decreased by 2.83%, indicating that investor sentiment is improving.
  • Dividend Yield

    Candel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Candel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.11% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently decreased by 2.83%, indicating that investor sentiment is improving.
  • News Sentiment

    Candel Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Candel Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    8 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,540.00 in company stock.

  • Percentage Held by Insiders

    16.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.93% of the stock of Candel Therapeutics is held by institutions.

  • Read more about Candel Therapeutics' insider trading history.
Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CADL Stock News Headlines

Analysts Set Candel Therapeutics, Inc. (NASDAQ:CADL) Price Target at $20.00
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Candel Therapeutics secures $130M to fund lead program – ICYMI
See More Headlines

CADL Stock Analysis - Frequently Asked Questions

Candel Therapeutics' stock was trading at $8.68 on January 1st, 2025. Since then, CADL shares have decreased by 37.7% and is now trading at $5.4050.

Candel Therapeutics, Inc. (NASDAQ:CADL) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08.

Candel Therapeutics (CADL) raised $72 million in an initial public offering on Tuesday, July 27th 2021. The company issued 9,000,000 shares at a price of $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Top institutional investors of Candel Therapeutics include Halter Ferguson Financial Inc. (1.27%) and HB Wealth Management LLC (0.11%). Insiders that own company stock include Paul B Manning, Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, Seshu Tyagarajan, William Garrett Nichols, Charles Schoch, Jason Amello and Joseph C Papa.
View institutional ownership trends
.

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V).

Company Calendar

Last Earnings
8/14/2025
Today
10/24/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CADL
CIK
1841387
Fax
N/A
Employees
60
Year Founded
1999

Price Target and Rating

High Price Target
$25.00
Low Price Target
$7.00
Potential Upside/Downside
+261.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.18 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.00%
Return on Assets
-26.81%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
7.04
Quick Ratio
7.04

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
3.77

Miscellaneous

Outstanding Shares
54,895,000
Free Float
45,782,000
Market Cap
$291.49 million
Optionable
Optionable
Beta
-0.94

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CADL) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners